AstraZeneca Vaccine Found 79% Effective In US Trials

The vaccine was 100% effective against severe or critical disease and hospitalisation and was safe, the drugmaker said on Monday, releasing results of the late-stage human trial study of more than 32,000 volunteers across all age groups.

The COVID-19 vaccine developed by Oxford University and AstraZeneca was 79% effective in preventing symptomatic illness a large trial in the United States, Chile and Peru, the company said on Monday, paving the way for it to apply for US approval. The vaccine was 100% effective against severe or critical disease and hospitalisation and was safe, the drugmaker said on Monday, releasing results of the late-stage human trial study of more than 32,000 volunteers across all age groups. The data will give credence to the British shot after results from earlier, separate late-stage studies raised questions about the robustness of the data. It will also help allay safety concerns that have disrupted its use in the European Union after a small number of reports of rare blood clots in people who have received the shot.